688 related articles for article (PubMed ID: 26290635)
21. cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells.
Fu H; He Y; Qi L; Chen L; Luo Y; Chen L; Li Y; Zhang N; Guo H
Cancer Lett; 2017 Sep; 403():260-270. PubMed ID: 28649002
[TBL] [Abstract][Full Text] [Related]
22. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
23. PKM2 gene regulates the behavior of pancreatic cancer cells via mitogen-activated protein kinase pathways.
Feng J; Ma T; Ge Z; Lin J; Ding W; Chen H; Zhu W; Zhou S; Tan Y
Mol Med Rep; 2015 Mar; 11(3):2111-7. PubMed ID: 25411978
[TBL] [Abstract][Full Text] [Related]
24. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells.
Han B; Liu SH; Guo WD; Zhang B; Wang JP; Cao YK; Liu J
World J Gastroenterol; 2015 Sep; 21(33):9727-35. PubMed ID: 26361419
[TBL] [Abstract][Full Text] [Related]
25. Lapatinib Inhibits Breast Cancer Cell Proliferation by Influencing PKM2 Expression.
Guan M; Tong Y; Guan M; Liu X; Wang M; Niu R; Zhang F; Dong D; Shao J; Zhou Y
Technol Cancer Res Treat; 2018 Jan; 17():1533034617749418. PubMed ID: 29343208
[TBL] [Abstract][Full Text] [Related]
26. EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.
Yang W; Xia Y; Cao Y; Zheng Y; Bu W; Zhang L; You MJ; Koh MY; Cote G; Aldape K; Li Y; Verma IM; Chiao PJ; Lu Z
Mol Cell; 2012 Dec; 48(5):771-84. PubMed ID: 23123196
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of Pyruvate Kinase M2 Inhibits Cell Proliferation, Metabolism, and Migration in Renal Cell Carcinoma.
Dey P; Son JY; Kundu A; Kim KS; Lee Y; Yoon K; Yoon S; Lee BM; Nam KT; Kim HS
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717694
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Proliferation, Migration, and Invasion by Knockdown of Pyruvate Kinase-M2 (PKM2) in Ovarian Cancer SKOV3 and OVCAR3 Cells.
Miao Y; Lu M; Yan Q; Li S; Feng Y
Oncol Res; 2016 Oct; 24(6):463-475. PubMed ID: 28281967
[TBL] [Abstract][Full Text] [Related]
29. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
30. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic silencing of miR-338 facilitates glioblastoma progression by de-repressing the pyruvate kinase M2-β-catenin axis.
Han B; Meng X; Chen H; Chen L; Liu X; Wang H; Liu D; Gao F; Lin L; Ming J; Sun B; Yin S; Wang R; Wu P; Cai J; Jiang C
Aging (Albany NY); 2017 Aug; 9(8):1885-1897. PubMed ID: 28858851
[TBL] [Abstract][Full Text] [Related]
32. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
33. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
[TBL] [Abstract][Full Text] [Related]
34. AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-κB axis.
Zheng B; Geng L; Zeng L; Liu F; Huang Q
Cell Signal; 2018 May; 45():122-131. PubMed ID: 29374601
[TBL] [Abstract][Full Text] [Related]
35. Metalloproteinase meprin α regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein Reptin.
Breig O; Yates M; Neaud V; Couchy G; Grigoletto A; Lucchesi C; Prox J; Zucman-Rossi J; Becker-Pauly C; Rosenbaum J
Oncotarget; 2017 Jan; 8(5):7839-7851. PubMed ID: 27999200
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
37. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
Liu AM; Xu Z; Shek FH; Wong KF; Lee NP; Poon RT; Chen J; Luk JM
PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
[TBL] [Abstract][Full Text] [Related]
38. Oncogene Delta/Notch-Like EGF-Related Receptor Promotes Cell Proliferation, Invasion, and Migration in Hepatocellular Carcinoma and Predicts a Poor Prognosis.
Liang Y; Luo H; Zhang H; Dong Y; Bao Y
Cancer Biother Radiopharm; 2018 Nov; 33(9):380-386. PubMed ID: 30235011
[TBL] [Abstract][Full Text] [Related]
39. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma.
Dayton TL; Gocheva V; Miller KM; Israelsen WJ; Bhutkar A; Clish CB; Davidson SM; Luengo A; Bronson RT; Jacks T; Vander Heiden MG
Genes Dev; 2016 May; 30(9):1020-33. PubMed ID: 27125672
[TBL] [Abstract][Full Text] [Related]
40. Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells.
Jung Y; Jang YJ; Kang MH; Park YS; Oh SJ; Lee DC; Xie Z; Yoo HS; Park KC; Yeom YI
Mol Cells; 2013 Apr; 35(4):335-41. PubMed ID: 23515579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
